Rho GDP dissociation inhibitor α expression correlates with the outcome of CMF treatment in invasive ductal breast cancer

  • Authors:
    • Henrike Ronneburg
    • Paul N. Span
    • Eva Kantelhardt
    • Angela Dittmer
    • Dario Schunke
    • Hans-Jürgen Holzhausen
    • Fred C.G.J. Sweep
    • Jürgen Dittmer
  • View Affiliations

  • Published online on: February 1, 2010     https://doi.org/10.3892/ijo_00000510
  • Pages: 379-386
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rho-GDIα is an inhibitor of Rho-GTPases, which is involved in cancer progression. Little is known about its role in breast cancer progression. There is evidence, that Rho-GDIα may modulate drug resistance of breast cancer cells. To assess the importance of Rho-GDIα as a risk factor in invasive ductal breast cancer, cancer specimens of three groups of patients were analyzed for Rho-GDIα RNA (group 1, N=72 and group 2, N=73) or protein expression (group 3, N=90). In group 1, patients did not receive any adjuvant treatment, whereas, in groups 2 and 3, patients were treated with anti-estrogens and/or with chemotherapeutical drugs. Rho-GDIα RNA levels, measured by RT-PCR from fresh-frozen material, did not correlate with relapse-free survival in Kaplan-Meier analysis, except in a subgroup of CMF-only treated patients. In this subgroup, higher Rho-GDIα RNA levels were significantly associated with more favorable prognosis. Immunohistochemical analysis (group 3) confirmed the link between higher Rho-GDIα expression and better outcome. This was again particularly true for the CMF-only treated patients. Cox regression analysis revealed that high Rho-GDIα protein expression reduced the risk for a relapse by ≈3-fold, even if adjusted for grading, tumor size, nodal and estrogen receptor (ER) status. The data suggest that Rho-GDIα is beneficial to patients who received adjuvant chemotherapy. Rho-GDIα is possibly a useful biomarker to predict the response of breast cancer patients to CMF treatment.

Related Articles

Journal Cover

February 2010
Volume 36 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ronneburg H, Span PN, Kantelhardt E, Dittmer A, Schunke D, Holzhausen H, Sweep FC and Dittmer J: Rho GDP dissociation inhibitor α expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. Int J Oncol 36: 379-386, 2010
APA
Ronneburg, H., Span, P.N., Kantelhardt, E., Dittmer, A., Schunke, D., Holzhausen, H. ... Dittmer, J. (2010). Rho GDP dissociation inhibitor α expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. International Journal of Oncology, 36, 379-386. https://doi.org/10.3892/ijo_00000510
MLA
Ronneburg, H., Span, P. N., Kantelhardt, E., Dittmer, A., Schunke, D., Holzhausen, H., Sweep, F. C., Dittmer, J."Rho GDP dissociation inhibitor α expression correlates with the outcome of CMF treatment in invasive ductal breast cancer". International Journal of Oncology 36.2 (2010): 379-386.
Chicago
Ronneburg, H., Span, P. N., Kantelhardt, E., Dittmer, A., Schunke, D., Holzhausen, H., Sweep, F. C., Dittmer, J."Rho GDP dissociation inhibitor α expression correlates with the outcome of CMF treatment in invasive ductal breast cancer". International Journal of Oncology 36, no. 2 (2010): 379-386. https://doi.org/10.3892/ijo_00000510